Friday is symposium day at the 62nd ASH Annual Meeting. These symposia are precursors to the official ASH meeting. Each is generally 2-3 hours long. At the symposium hosted by Dr. Brian G.M. Durie and the International Myeloma Foundation, they presented actual patient case-studies, asking the panel, and the audience, how they would treat these […]
Friday, the International Myeloma Foundation held its annual symposium at #ASH20. This has always been a highlight for me as it’s a primer of what’s to come with all the abstracts throughout the weekend. This CME-certified webinar featuring discussion of patient-case studies and key clinical trial data by renowned clinical experts providing their perspectives on […]
Minimal Residual Disease (-) (meaning no detectable disease) has become the agreed goal of most myeloma clinical trials. MRD (-) status is a predictor of good outcome. As we patients progress with treatment we want to know if we have reached MRD (-) or not, however it is defined, and by whichever method it is measured. […]
The American Society of Hematology’s Annual Meeting (ASH) has just begun, but thanks to the pre-ASH Scientific Workshops, On-Demand Sessions, and Satellite Symposia, my head is already spinning. Much of what I heard in the scientific workshops was above my head, but provided me with hope. Each year when I attend ASH, I leave thinking, […]
The life expectancy of standard-risk myeloma patients has increased significantly in the last decade, thanks to novel therapies. Some trials that are in progress, such as the MAIA trial comparing Revilmid and dexamethasone (Rd) versus Daratumumab, Revilmid and dexamethasone (DRd) have not yet met their progression-free survival (PFS) end state and are at more than […]
Thanks to my dexamethasone today, I’m writing this in the wee hours of Saturday morning, and the All-Virtual 62nd American Society of Hematology (ASH) Meeting and Exposition kicks off in and few hours. It will include many abstracts (research presentations) about the future of multiple myeloma treatments. But even before ASH begins, the International Myeloma […]
The Friday before the official start of ASH is always considered Symposium day. However, even before Friday, there are typically more meetings of different groups. And even though this year’s 62nd American Society of Hematology (ASH) meeting is virtual, there’s no exception to pre-Symposium day meetings and I’ve attended three already. The first was a […]
It’s the year 2020 which is a notable year for reasons beside being a global pandemic. For me, 2020 marks my 20th year of survival with multiple myeloma. I am deeply grateful for all the research that has taken place and hopeful for the future of myeloma, all while waiting for a cure. In 2000, […]
Hi Everyone! Welcome to ASH 2020 style: what else but virtual! This PRE-ASH blog is my way of sharing with you *highlights of the past to help us refresh our memories and to prepare us for #ASH20! It’s also about reading up on the various “ASH Top 10 for 2020” lists. Here is Dr. Brian […]
I entered 2020 with plans that involved me stepping outside of my comfort zone. Some of my goals were to try new things, to get out more to enjoy enriching experiences, and to have some fun along the way. I am happy to say that many of my goals have come to fruition. I could […]
